Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05705531 · ClinicalTrials.gov registry record
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
A clinical trial of Classic Hodgkin Lymphoma and Clonal Hematopoiesis, sponsored by Children's Oncology Group.
- Recruiting
- Registry status
- 190
- Enrollment target
- 20
- Study locations
NCT05705531 is a study of Classic Hodgkin Lymphoma and Clonal Hematopoiesis that is actively recruiting participants, run by Children's Oncology Group. The registered enrollment target is 190 participants, below the 232-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT05705531, a study of Classic Hodgkin Lymphoma and Clonal Hematopoiesis, is actively recruiting participants, sponsored by Children's Oncology Group.
- RECRUITING
- Registry status
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- OTHER Survey Administration
- OTHER Electronic Health Record Review
- PROCEDURE Archive Sample Retrieval
Study Locations (20)
Florida
- Golisano Children's Hospital of Southwest Florida - Fort Myers
- Arnold Palmer Hospital for Children - Orlando
- Saint Joseph's Hospital/Children's Hospital-Tampa - Tampa
New York
- Albany Medical Center - Albany
- Roswell Park Cancer Institute - Buffalo
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Alabama
- USA Health Strada Patient Care Center - Mobile
Arizona
- Phoenix Childrens Hospital - Phoenix
Connecticut
- Yale University - New Haven
Delaware
- Alfred I duPont Hospital for Children - Wilmington
Georgia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2023-08-18 |
| Est. Completion | 2028-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05705531
The ClinicalTrials.gov registry entry for NCT05705531 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (18% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05705531 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT05705531 about?
NCT05705531 is a clinical study titled "A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma". This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health....
What is the current status of trial NCT05705531?
This trial is currently recruiting. The enrollment target is 190 participants. The study started on 2023-08-18. Estimated completion is 2028-10-01.
What conditions does trial NCT05705531 study?
This clinical trial studies the following conditions: Classic Hodgkin Lymphoma, Clonal Hematopoiesis, Cardiovascular Disorder.
What interventions are being tested in trial NCT05705531?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Survey Administration (OTHER), Electronic Health Record Review (OTHER), Archive Sample Retrieval (PROCEDURE).
Who is sponsoring clinical trial NCT05705531?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05705531 being conducted?
This trial has 20 study locations across Alabama, Arizona, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Classic Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
RECRUITING · Phase 2
-
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
RECRUITING · Phase 2
-
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.